AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11135715 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular rapacuronium 2.8 mg/kg in infants
Number of subjects: 96
Study 11135715 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular rapacuronium 4.8 mg/kg in children
Number of subjects: 96
Study 11135715 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular rapacuronium (both doses)
Number of subjects: 96
Study 9820916 — intervention group
Group type: EXPERIMENTAL
Intervention: Early active training program
Number of subjects: 52
Study 9820916 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional, less active training program)
Number of subjects: 52
Study 7605424 — intervention group
Group type: EXPERIMENTAL
Intervention: INR system using three thromboplastin reagents
Number of subjects: 29
Study 7605424 — intervention group
Group type: COMPARATOR
Intervention: Control patients on warfarin (n = 31)
Number of subjects: 29
Study 7605424 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen, factors V, II and X
Number of subjects: 29
Study 7605424 — intervention group
Group type: EXPERIMENTAL
Intervention: FDP's
Number of subjects: 29
Study 2731163 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral supplementation with beta-carotene (90 mg twice weekly for 4 weeks)
Number of subjects: 36
Study 2731163 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 36
Study 31139989 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm saline
Number of subjects: 96
Study 31139989 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-fog solution
Number of subjects: 96
Study 31139989 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 96
Study 31139989 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 96
Study 29739378 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D concentrations ≥30 ng/ml
Number of subjects: 284
Study 29739378 — intervention group
Group type: COMPARATOR
Intervention: Serum 25-hydroxyvitamin D concentrations <30 ng/ml
Number of subjects: 284
Study 29739378 — intervention group
Group type: EXPERIMENTAL
Intervention: Median serum 25(OH)D concentrations
Number of subjects: 284
Study 29739378 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall vitamin D deficiency prevalence
Number of subjects: 284
Study 27271833 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential currents for psoriasis treatment
Number of subjects: 594
Study 27271833 — intervention group
Group type: COMPARATOR
Intervention: Standard medicamentous therapy for psoriasis treatment
Number of subjects: 594
Study 27271833 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential currents for eczema treatment
Number of subjects: 594
Study 27271833 — intervention group
Group type: COMPARATOR
Intervention: Standard medicamentous therapy for eczema treatment
Number of subjects: 594
Study 25331573 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prescribing
Number of subjects: 279
Study 25331573 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of AAD
Number of subjects: 279
Study 25331573 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-amoxiclav
Number of subjects: 279
Study 25331573 — intervention group
Group type: EXPERIMENTAL
Intervention: Incontinence pads usage
Number of subjects: 279
Study 25331573 — intervention group
Group type: EXPERIMENTAL
Intervention: Residential homes
Number of subjects: 279
Study 25331573 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic-resistant isolates
Number of subjects: 279
Study 22633965 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal vessel movement in eyes with ERM
Number of subjects: 206
Study 21028985 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose artesunate therapy (4 mg/kg/day orally for 7 days)
Number of subjects: 94
Study 21028985 — intervention group
Group type: COMPARATOR
Intervention: Quinine-tetracycline
Number of subjects: 94
Study 18402857 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 114
Study 18402857 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 114
Study 15811479 — intervention group
Group type: EXPERIMENTAL
Intervention: Manidipine 10 mg once daily for 24 weeks
Number of subjects: 111
Study 15811479 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10 mg once daily for 24 weeks
Number of subjects: 111
Study 12219857 — intervention group
Group type: EXPERIMENTAL
Intervention: Social exclusion feedback (telling individuals they are likely to end up alone later in life)
Number of subjects: 0
Study 12219857 — intervention group
Group type: EXPERIMENTAL
Intervention: Social exclusion feedback
Number of subjects: 0
Study 12219857 — intervention group
Group type: COMPARATOR
Intervention: Control group feedback (telling individuals their future would be marred by frequent accidents)
Number of subjects: 0
Study 11224967 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapist contact
Number of subjects: 104
Study 11224967 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum therapist contact
Number of subjects: 104
Study 11224967 — intervention group
Group type: COMPARATOR
Intervention: Bibliotherapy
Number of subjects: 104
Study 8974213 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin therapy (20 mg twice daily)
Number of subjects: 429
Study 8974213 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label adjunctive cholestyramine (for patients with mean prerandomization LDL cholesterol of 160 mg/dL or higher)
Number of subjects: 429
Study 8974213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 429
Study 14621733 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists (CATs)
Number of subjects: 0
Study 3830764 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 120 mg every 8 hours for three consecutive days
Number of subjects: 20
Study 3830764 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered with the same regimen
Number of subjects: 20
Study 3830764 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 20
Study 30819640 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-provided medication therapy management program
Number of subjects: 400
Study 30819640 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 400
Study 29580132 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity group (P); moderate to vigorous exercise (20 min, 3 times per week, 6 weeks) while learning times tables
Number of subjects: 85
Study 29580132 — intervention group
Group type: COMPARATOR
Intervention: Control group (C); seated classroom approach while learning times tables
Number of subjects: 85
Study 29580132 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity group (P)
Number of subjects: 85
Study 29580132 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 85
Study 29580132 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 85
Study 26962396 — intervention group
Group type: EXPERIMENTAL
Intervention: Snello cookie (HFHCM‐S)
Number of subjects: 10
Study 26962396 — intervention group
Group type: COMPARATOR
Intervention: Control cookies (HFHCM‐C)
Number of subjects: 10
Study 24548353 — intervention group
Group type: EXPERIMENTAL
Intervention: Traffic light bougie
Number of subjects: 40
Study 24548353 — intervention group
Group type: COMPARATOR
Intervention: Conventional bougie
Number of subjects: 40
Study 22317945 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg zolpidem
Number of subjects: 11
Study 22317945 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg zolpidem
Number of subjects: 11
Study 22317945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 20122433 — intervention group
Group type: EXPERIMENTAL
Intervention: Midpalatal miniscrews
Number of subjects: 128
Study 20122433 — intervention group
Group type: EXPERIMENTAL
Intervention: Midpalatal miniscrews with splinting
Number of subjects: 128
Study 18269774 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin-bound paclitaxel 100 mg/m2
Number of subjects: 181
Study 18269774 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin-bound paclitaxel 125 mg/m2
Number of subjects: 181
Study 16223400 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% plus 0.5 mg/kg ketamine
Number of subjects: 80
Study 16223400 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% plus 0.5 mg/kg ketamine
Number of subjects: 80
Study 16223400 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.25%
Number of subjects: 80
Study 16223400 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.2%
Number of subjects: 80
Study 16223400 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 80
Study 11691535 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter closure of ASD
Number of subjects: 38
Study 9163650 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline with 2 L x min(‐1) oxygen
Number of subjects: 17
Study 9163650 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg morphine with 2 L x min(‐1) oxygen
Number of subjects: 17
Study 9163650 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg morphine with 2 L x min(‐1) oxygen
Number of subjects: 17
Study 9163650 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg morphine without oxygen (prongs fixed, no flow)
Number of subjects: 17
Study 7832871 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed jogging 3 times per week for 4 weeks
Number of subjects: 30
Study 7832871 — intervention group
Group type: COMPARATOR
Intervention: Control group (no programmed jogging)
Number of subjects: 30
Study 3118752 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunnelled catheters
Number of subjects: 81
Study 3118752 — intervention group
Group type: COMPARATOR
Intervention: Non-tunnelled catheters
Number of subjects: 81
Study 1973472 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate 15 mg weekly
Number of subjects: 69
Study 1973472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 4571398 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of terbutaline (0.075 mg/kg)
Number of subjects: 30
Study 4571398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 29471460 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person coaching
Number of subjects: 148
Study 29471460 — intervention group
Group type: COMPARATOR
Intervention: Webinar coaching
Number of subjects: 148
Study 28768263 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline rectal washout (RW)
Number of subjects: 61
Study 28768263 — intervention group
Group type: COMPARATOR
Intervention: Glycerin suppositories (GS)
Number of subjects: 61
Study 25900749 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin 5000 units once daily for 2 weeks
Number of subjects: 265
Study 25900749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study 24072754 — intervention group
Group type: EXPERIMENTAL
Intervention: Relatives' Education And Coping Toolkit (REACT) intervention
Number of subjects: 103
Study 24072754 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 103
Study 20848523 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0
Study 20848523 — intervention group
Group type: COMPARATOR
Intervention: Traditional non-biologic therapies
Number of subjects: 0
Study 19817934 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive blood pressure goals (< or =115/75 mm Hg)
Number of subjects: 0
Study 19817934 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure goals (< or =130/80 mm Hg)
Number of subjects: 0
Study 17047290 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide
Number of subjects: 10
Study 17047290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 14709579 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% oxygen (FIO2 of 0.80)
Number of subjects: 165
Study 14709579 — intervention group
Group type: COMPARATOR
Intervention: 35% oxygen (FIO2 of 0.35)
Number of subjects: 165
Study 14709579 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 165
Study 14709579 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with SSI
Number of subjects: 165
Study 11229782 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant drugs (specific drugs not mentioned)
Number of subjects: 0
Study 9115917 — intervention group
Group type: EXPERIMENTAL
Intervention: Water exposure (15 min twice daily for 2 weeks)
Number of subjects: 21
Study 9115917 — intervention group
Group type: COMPARATOR
Intervention: Control (no water exposure)
Number of subjects: 21
Study 7957349 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine-123 labelled low-density lipoprotein (123I-LDL)
Number of subjects: 2
Study 7957349 — intervention group
Group type: EXPERIMENTAL
Intervention: Indium-111 labelled low-density lipoprotein (111In-LDL)
Number of subjects: 2
Study 3310576 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (mean 216 mg/day)
Number of subjects: 25
Study 3310576 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (mean 80 mg/day)
Number of subjects: 25
Study 3310576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 29801496 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Campaigns (CHCs)
Number of subjects: 4941
Study 29801496 — intervention group
Group type: COMPARATOR
Intervention: Clinics
Number of subjects: 4941
Study 27013248 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise stress echo (ESE)
Number of subjects: 385
Study 27013248 — intervention group
Group type: COMPARATOR
Intervention: Exercise electrocardiography (ExECG)
Number of subjects: 385
Study 25929253 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg
Number of subjects: 152
Study 25929253 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 152
Study 23782792 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging guided left ventricular lead positioning
Number of subjects: 192
Study 22127693 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 100 mg plus MTX
Number of subjects: 637
Study 22127693 — intervention group
Group type: COMPARATOR
Intervention: placebo plus MTX
Number of subjects: 637
Study 19130931 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab treatment
Number of subjects: 0
Study 16968350 — intervention group
Group type: EXPERIMENTAL
Intervention: DDMI (two-session motivational interview)
Number of subjects: 44
Study 16968350 — intervention group
Group type: COMPARATOR
Intervention: SI (two-session standard psychiatric interview)
Number of subjects: 44
Study 15458233 — intervention group
Group type: EXPERIMENTAL
Intervention: LIG-2 (1%w/w IDU in 5%w/w HPMC K4M gel base)
Number of subjects: 20
Study 15458233 — intervention group
Group type: EXPERIMENTAL
Intervention: LIG-1 (1%w/w IDU in 2%w/w HPMC K4M gel base)
Number of subjects: 20
Study 15458233 — intervention group
Group type: COMPARATOR
Intervention: LIG-1 and LIG-2
Number of subjects: 20
Study 15458233 — intervention group
Group type: COMPARATOR
Intervention: LIG-1
Number of subjects: 20
Study 15458233 — intervention group
Group type: COMPARATOR
Intervention: LIG-2
Number of subjects: 20
Study 11275394 — intervention group
Group type: EXPERIMENTAL
Intervention: St. John's wort (3 tablets each containing 900 microg total hypericin, for 5 weeks)
Number of subjects: 54
Study 11275394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 11275394 — intervention group
Group type: EXPERIMENTAL
Intervention: St. John's wort
Number of subjects: 54
Study 9395363 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (125 mg/day)
Number of subjects: 72
Study 9395363 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (250 mg/day)
Number of subjects: 72
Study 9395363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 7955817 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (1.0 mg)
Number of subjects: 9
Study 7955817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 3555585 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg plus hydrochlorothiazide 25 mg, given twice daily for 1 month
Number of subjects: 10
Study 3555585 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg plus hydrochlorothiazide 25 mg, given once daily for 1 month
Number of subjects: 10
Study 3555585 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg plus hydrochlorothiazide 25 mg, given once or twice daily for 2 months
Number of subjects: 10
Study 31703750 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 96
Study 31703750 — intervention group
Group type: EXPERIMENTAL
Intervention: Training therapy
Number of subjects: 96
Study 31703750 — intervention group
Group type: EXPERIMENTAL
Intervention: Training plus acupuncture
Number of subjects: 96
Study 31703750 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 96
Study 28691640 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty fish
Number of subjects: 478
Study 28691640 — intervention group
Group type: COMPARATOR
Intervention: Meat
Number of subjects: 478
Study 28691640 — intervention group
Group type: COMPARATOR
Intervention: n-3 supplements
Number of subjects: 478
Study 25081280 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg)
Number of subjects: 80
Study 25081280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 23452397 — intervention group
Group type: EXPERIMENTAL
Intervention: TREPP mesh repair
Number of subjects: 800
Study 23452397 — intervention group
Group type: COMPARATOR
Intervention: TIPP procedure
Number of subjects: 800
Study 21034290 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 1230
Study 21034290 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 1230
Study 21034290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1230
Study 18304580 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐Hz rTMS
Number of subjects: 10
Study 18304580 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 10
Study 16413753 — intervention group
Group type: EXPERIMENTAL
Intervention: High olive oil diet
Number of subjects: 21
Study 16413753 — intervention group
Group type: COMPARATOR
Intervention: High carbohydrate, low olive oil diet
Number of subjects: 21
Study 12826020 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphaphenazole (0.02-2 mg/min)
Number of subjects: 11
Study 12826020 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphaphenazole (6 mg/min) after L-NMMA (16 micromol/min) and ibuprofen (1200 mg, orally)
Number of subjects: 11
Study 12826020 — intervention group
Group type: COMPARATOR
Intervention: L-NMMA (4 micromol/min) and ibuprofen (1200 mg, orally)
Number of subjects: 11
Study 10883425 — intervention group
Group type: EXPERIMENTAL
Intervention: New positioning device for precise femoral insertion of the ACL autograft
Number of subjects: 0
Study 10883425 — intervention group
Group type: COMPARATOR
Intervention: Other positioning procedures
Number of subjects: 0
Study 8925987 — intervention group
Group type: EXPERIMENTAL
Intervention: Short parenteral treatment with antibiotics (exact dosage and duration not specified)
Number of subjects: 63
Study 8925987 — intervention group
Group type: COMPARATOR
Intervention: Conventional long course treatment with antibiotics (exact dosage and duration not specified)
Number of subjects: 63
Study 1598444 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP group
Number of subjects: 22
Study 1598444 — intervention group
Group type: EXPERIMENTAL
Intervention: lobar CPAP group
Number of subjects: 22
Study 1598444 — intervention group
Group type: COMPARATOR
Intervention: lobar CPAP
Number of subjects: 22
Study 1598444 — intervention group
Group type: COMPARATOR
Intervention: total lung CPAP ventilation
Number of subjects: 22
Study 6693780 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated liquid preparation of 8‐MOP
Number of subjects: 12
Study 6693780 — intervention group
Group type: COMPARATOR
Intervention: Oxsoralen
Number of subjects: 12
Study 31566209 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 109
Study 31566209 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 109
Study 30147307 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol (FP/SAL) 250/50 µg
Number of subjects: 406
Study 30147307 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium bromide (TIO) 18 µg
Number of subjects: 406
Study 25821315 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNα2a, RBV and Q‐e‐I (5 g, orally, thrice daily in divided doses)
Number of subjects: 60
Study 25821315 — intervention group
Group type: COMPARATOR
Intervention: IFNα2a, RBV and placebo
Number of subjects: 60
Study 25821315 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNα2a, RBV and Q‐e‐I
Number of subjects: 60
Study 24219376 — intervention group
Group type: COMPARATOR
Intervention: 1.5 g/day of ResistAid
Number of subjects: 75
Study 24219376 — intervention group
Group type: COMPARATOR
Intervention: 4.5 g/day of ResistAid
Number of subjects: 75
Study 24219376 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 75
Study 19308728 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally guided peer support in addition to care as usual (CAU)
Number of subjects: 106
Study 19308728 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU) only
Number of subjects: 106
Study 19767527 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antioxidant (AO) cocktail (vitamins C and E and alpha-lipoic acid)
Number of subjects: 12
Study 19767527 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 12
Study 17534808 — intervention group
Group type: EXPERIMENTAL
Intervention: ThinOptX IOL implantation
Number of subjects: 25
Study 17534808 — intervention group
Group type: COMPARATOR
Intervention: AcrySof IOL implantation
Number of subjects: 25
Study 15543118 — intervention group
Group type: EXPERIMENTAL
Intervention: Detergent-free whitening dentifrice
Number of subjects: 20
Study 15543118 — intervention group
Group type: COMPARATOR
Intervention: Fluoride-matched comparator
Number of subjects: 20